Diabetes Remission After LRYGBP With and Without Fundus Resection: a Randomized Clinical Trial

• Published in: Obesity surgery 2023-11, Vol.33 (11), p.3373-3382
• Main Authors: Kehagias, Dimitrios, Lampropoulos, Charalampos, Georgopoulos, Neoklis, Habeos, Ioannis, Kalavrizioti, Dimitra, Vamvakas, Sotirios-Spyridon, Davoulou, Panagiota, Kehagias, Ioannis
• Format: Article
• Language: English
• Subjects: Body mass index; Diabetes; Gastrointestinal surgery; Glucose; Medicine; Medicine & Public Health; Original Contributions; Peptides; Surgery
• ISSN: 0960-8923; 1708-0428
• DOI: 10.1007/s11695-023-06857-z

Background Glycemic control, after metabolic surgery, is achieved in two stages, initially with neuroendocrine alterations and in the long-term with sustainable weight loss. The resection of the gastric fundus, as the major site of ghrelin production, is probably related with optimized glucose regulation. The aim of the present study is to investigate whether the modification of laparoscopic Roux-en-Y gastric bypass (LRYGBP) with fundus resection offers superior glycemic control, compared to typical LRYGBP. Materials and Methods Participants were 24 patients with body mass index (BMI) ≥40kg/m 2 and type II diabetes mellitus (T2DM), who were randomly assigned to undergo LRYGBP and LRYGBP with fundus resection (LRYGBP+FR). Gastrointestinal (GI) hormones [ghrelin, glucagon-like-peptide-1 (GLP-1), peptide-YY (PYY)] and glycemic parameters (glucose, insulin, HbA1c, C-peptide, insulinogenic index, HOMA-IR) were measured preoperatively, at 6 and 12 months during an oral glucose tolerance test (OGTT). Results Ninety-five percent of patients showed complete remission of T2DM after 12 months. LRYGBP+FR was not related with improved glycemic control, compared to LRYGBP. Ghrelin levels were not significantly reduced at 6 and 12 months after LRYGBP+FR. GLP-1 and PYY levels were remarkably increased postprandially in both groups at 6 and 12 months postoperatively ( p